Camurus AB   Report issue

For profit Phase 2 Phase 3
Founded: Lund Sweden (1991)

Organization Overview

First Clinical Trial
2014
NCT02212197
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Camurus AB

Active Ingredients

Drugs in Phase 3 Trials (2)

lanreotide (somatuline depot) (1 trial)

octreotide (sandostatin) (4 trials)

Drugs in Phase 2 Trials (1)

leuprolide (lupron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acromegaly (Phase 3)

Neuroendocrine Tumors (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3